9 Feb 2022″ SOURCE: REUTERS
Pfizer Inc ayaa sheegtay Talaadadii inay rajaynayso 2022 iibinta tallaalkeeda COVID-19 iyo kaniiniga ka hortagga fayraska inay ugu sarreeyaan $ 54bn, laakiin taasi waxay hoos uga dhacday qiyaasta sare ee Wall Street saamiyadeeduna waxay hoos uga dhaceen 3 boqolkiiba.
Maamulaha guud Albert Bourla wuxuu leeyahay iibka kama dambaysta ah ee COVID-19 ka hortagga fayraska Paxlovid wuxuu noqon karaa “mid ka weyn” saadaasha.
Si kastaba ha noqotee, madaxa fulinta Albert Bourla wuxuu yiri iibka kama dambaysta ah ee ka hortagga fayraska COVID-19 ee afka, Paxlovid, wuxuu noqon karaa “si ka weyn” waxa Pfizer saadaaliyay maadaama ay hadda aragtideeda ku jirto oo keliya qandaraasyo la saxiixay ama ku dhow.
Pfizer waxay hadda filaysaa $22bn sanadka 2022 iibinta daawaynta, marka la barbar dhigo qiyaasaha Wall Street ee $22.88bn.
“Sida cad, tani waa qayb yar oo ka mid ah 120ka milyan ee daawaynta ee aan hadda isku diyaarineyno inaan soo saarno” sanadkan, Bourla ayaa u sheegay falanqeeyayaasha wicitaanka shirarka.
Shirkaddu waxa ay Maraykanka ka iibinaysaa 20 milyan oo koorasyo Paxlovid ah oo ku kacaya $530 koorsadii, laakiin Bourla waxa ay sheegtay in taasi ay ahayd qiimo gaar ah, sababtoo ah cabbirka dalabka.
Qiimaha inta badan wadamada dakhligoodu sarreeyo, ayuu yidhi, in ka badan ama ka yar ayaa la jaan qaadi doona qiimaha Merck & Co’s xafiiltanka daawaynta molnupiravir, oo ay dawladda Maraykanku ku iibsatay $700 koorsadii.
Maamulayaasha Pfizer ayaa sheegay in shirkaddu ay wadahadalo firfircoon kula jirto in ka badan 100 waddan oo ku saabsan Paxlovid waxayna awood u leedahay inay sare u qaado 120 milyan oo koorso haddii loo baahdo.
Tallaalka COVID-19 ee Pfizer ee lagu sameeyay BioNTech SE ee Jarmalka, dawo-sameeyaha Mareykanka ayaa ka digay in iibka ugu dambeeya ee sanadka uusan kor u qaadin saadaasha hadda ee $ 32bn, 13 boqolkiiba hoos u dhac ah heerarka 2021.
Nooca Paxlovid oo la hagaajiyay
Sannadkii hore, shirkaddu waxay kordhisay saadaasha iibka tallaalka COVID dhowr jeer iyada oo saxeexday heshiisyo sahay oo badan oo adduunka ah.
Falanqeeyayaasha ayaa saadaaliyay iibka $33.79bn ee tallaalka sanadka 2022, marka loo eego xogta Refinitiv.
Guud ahaan, Pfizer waxay filaysaa iibka 2022 ee $98bn ilaa $102bn, sidoo kale wuxuu ka hooseeyaa qiyaasaha $105.48bn.
Dennis Dick, oo ah ganacsade gaar ah oo ka tirsan Bright Trading LLC ayaa yidhi: “Rajooyinku uma fiicna sida dib-u-fiirinta Pfizer hadda waana sababta (qiimaha saamiyada) uu hoos ugu dhacay warbixin hufan.
Horey u socoshada, “sida iska cad iibsiyada aad ayey ugu jiraan kaararka,” ayuu yiri Aamir Malik, madaxa hal-abuurka ganacsiga ee Pfizer.
Maalgashadayaasha qaarkood ayaa raadinayay Pfizer si ay ugu isticmaasho galitaanka lacagta caddaanka ah ee weyn ee alaabada COVID heshiisyada si ay u kiciso koritaanka mustaqbalka.
Pfizer waxay sheegtay inay billowday ka shaqaynta nooca jiilka soo socda ee Paxlovid, kaas oo loo oggolaaday in lagu daweeyo bukaannada halista ugu jira COVID-19 wax yar ka dib bilawga calaamadaha.
Paxlovid waxa uu si aad ah uga wanagsan yahay tijaabooyinkiisa kiliinikada marka loo eego kaniinka xafiiltama ee Merck
Laakiin Pfizer waxa laga yaabaa inay wali u baahan tahay nooca Paxlovid oo la hagaajiyay, sida uu qabo Davinderpreet Mangat, falanqeeye sare oo ka tirsan Informa Pharma Intelligence.
“Albaabku wax yar ayuu u furan yahay, weli, ee ka hortagga fayraska COVID,” Mangat ayaa yidhi. “Daawooyinka shirkadaha kale waxay awoodaan inay dhaafaan Paxlovid, oo la mid ah sida Paxlovid uu uga sarre maray daroogada Merck.”
XIGASHO: REUTERS